CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update

References

• Cancer facts and figures [Internet]. 2016 [cited 2016 Apr 22]. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
   Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21–27.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: NCCN Clinical Guidelines in Oncology. Breast Cancer [Internet]. V.I. 2016 [cited 2016 Apr 22]. Available from: www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643–658.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Res. 2012;72(suppl 24). Abstract nr S1-6.
   Google Scholar
• Letrozole (Femara) package insert. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Femara.pdf
   Google Scholar
• Finn RS, Crown JP, Boer K, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC) [abstract 100O]. Ann Oncol. 2012;23:ii43–ii45.
   Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• FDA approval of palbociclib and letrozole for first line treatment in postmenopausal women with HR-positive, HER2-negative advanced breast cancer. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm
   Google Scholar
• FDA approval palbociclib and fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12(6):676–684.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18(22):2699–2711.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (Georgetown, Tex). 2007;6(6):667–671.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–330.
   PubMed Web of Science ®Google Scholar
• Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs. 2015;26(8):797–806.
   PubMed Web of Science ®Google Scholar
• Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle (Georgetown, Tex). 2008;7(7):892–898.
   PubMed Web of Science ®Google Scholar
• Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006;7(9):667–677.
   PubMed Web of Science ®Google Scholar
• Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 2011;50(25):5566–5582.
   PubMed Web of Science ®Google Scholar
• Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 1998;395(6699):237–243.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512.
   PubMed Web of Science ®Google Scholar
• Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017–1021.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell. 2006;9(1):2–4.
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet. 2003;35(1):25–31.
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994;57(3):353–361.
   PubMed Web of Science ®Google Scholar
• Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995;90(1):43–50.
   PubMed Web of Science ®Google Scholar
• Landis MW, Pawlyk BS, Li T, et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9(1):13–22.
   PubMed Web of Science ®Google Scholar
• Reddy HKDL, Mettus RV, Rane SG, et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 2005;65(22):10174–10178.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438–451.
   PubMed Web of Science ®Google Scholar
• An HX, Beckmann MW, Reifenberger G, et al. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol. 1999;154(1):113–118.
   PubMed Web of Science ®Google Scholar
• Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8(8):2127–2133.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (Georgetown, Tex). 2010;9(20):4153–4163.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–190.
   PubMed Web of Science ®Google Scholar
• Tinoco G, Warsch S, Gluck S, et al. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4(2):117–132.
   PubMed Web of Science ®Google Scholar
• Said TK, Conneely OM, Medina D, et al. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology. 1997;138(9):3933–3939.
   PubMed Web of Science ®Google Scholar
• Altucci L, Addeo R, Cicatiello L, et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996;12(11):2315–2324.
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643.
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Green MD, Hall RE, et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983;19(5):615–621.
   PubMedGoogle Scholar
• Carroll JS, Prall OW, Musgrove EA, et al. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem. 2000;275(49):38221–38229.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247.
   PubMed Web of Science ®Google Scholar
• Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88(3):405–415.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018–4032.
   PubMed Web of Science ®Google Scholar
• Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–an overview and update. Mol Cell Endocrinol. 2015;418 Pt 3:220–234.
   PubMed Web of Science ®Google Scholar
• Bianco S, Gevry N. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription. 2012;3(4):165–170.
   PubMedGoogle Scholar
• Butt AJ, McNeil CM, Musgrove EA, et al. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 2005;12 Suppl 1:S47–59.
   PubMed Web of Science ®Google Scholar
• Perez-Tenorio G, Berglund F, Esguerra Merca A, et al. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. Int J Oncol. 2006;28(5):1031–1042.
   PubMed Web of Science ®Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253–267.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Conrad SE. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2005;280(18):17617–17625.
   PubMed Web of Science ®Google Scholar
• Bosco EE, Wang Y, Xu H, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 2007;117(1):218–228.
   PubMed Web of Science ®Google Scholar
• Riggins RB, Bouton AH, Liu MC, et al. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm. 2005;71:201–237.
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC. Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors. Int J Cancer Clin Res. 2015;2(4). pii: 029. Epub 2015 Oct 14.
   PubMedGoogle Scholar
• Jessen BA, Lee L, Koudriakova T, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol. 2007;27(2):133–142.
   PubMed Web of Science ®Google Scholar
• Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19(8):2319–2333.
   PubMed Web of Science ®Google Scholar
• Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol. 2005;23(9):1875–1884.
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJC, Petroni GR, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2013;137(2):483–492.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18(3):333–345.
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009;11(6):112.
   PubMed Web of Science ®Google Scholar
• Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014;7:203–215.
   PubMedGoogle Scholar
• Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012;287(34):29075–29087.
   PubMed Web of Science ®Google Scholar
• McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (Georgetown, Tex). 2012;11(14):2747–2755.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Heitjan D, et al. A phase II trial of an oral CDK4/6 inhibitor, PD0332991, in advanced breast cancer. J Clin Oncol. 2013;31(suppl; abstr 519).
   Google Scholar
• Slamon DJ, Hurvitz SA, Appelbaum S, et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer [abstract 3060]. J Clin Oncol. 2010;28:15s.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol. 2016;34(suppl; abstr 507).
   Google Scholar
• FDA approval of T-DM1 [ cited 24 Jul 2015]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htm
   Google Scholar
• Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014;5(7–8):261–272.
   PubMedGoogle Scholar
• Kim S, Loo A, Chopra R, et al. Abstract PR02: LEE011: an orally bioavailable, selective, small molecule inhibitor of CDK4/6- Reactivating Rb in cancer. Mol Cancer Ther. 2013;12:PR02.
   Google Scholar
• VanArsdale T, Boshoff C, Arndt KT, et al. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905–2910.
   PubMed Web of Science ®Google Scholar
• Bardia A, Modi S, Chavez-Mac Gregor M, et al. Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen-receptor positive, HER2-negative breast cancer (ER+/HER2- BC). J Clin Oncol. 2014;32(suppl):535a.
   Google Scholar
• Munster PN, Paige Hamilton E, Franklin C, et al. Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2- BC). J Clin Oncol. 2014;32(suppl):533a.
   Google Scholar
• Infante JR, Shapiro G, Witteveen P, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2014;32(suppl):2528a.
   Google Scholar
• Dempsey JA, Chan EM, Burke TF, et al. LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. Cancer Res. 2013;73(suppl):LB–122a.
   Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837.
   PubMed Web of Science ®Google Scholar
• Shapiro G, Rosen LS, Tolcher AW. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol. 2013;31(suppl):2500a.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J Clin Oncol. 2014;32(suppl):534a.
   Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. J Clin Oncol. 2016;34(suppl 15):510.
   PubMed Web of Science ®Google Scholar
• Rocca A, Farolfi A, Bravaccini S, et al. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother. 2014;15(3):407–420.
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Gucalp A, Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 2014;6:123–133.
   PubMedGoogle Scholar